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Chapter 1.1: Introduction
The concept of acute renal failure (ARF) has undergone
significant re-examination in recent years. Mounting evi-
dence suggests that acute, relatively mild injury to the kidney
or impairment of kidney function, manifest by changes in
urine output and blood chemistries, portend serious clinical
consequences.1–5 Traditionally, most reviews and textbook
chapters emphasize the most severe reduction in kidney
function, with severe azotemia and often with oliguria or
anuria. It has only been in the past few years that moderate
decreases of kidney function have been recognized as
potentially important, in the critically ill,2 and in studies
on contrast-induced nephropathy.4
Glomerular filtration rate and serum creatinine
The glomerular filtration rate (GFR) is widely accepted as the
best overall index of kidney function in health and disease.
However, GFR is difficult to measure and is commonly
estimated from the serum level of endogenous filtration
markers, such as creatinine. Recently, Chertow et al.1 found
that an increase of serum creatinine (SCr) of 40.3mg/dl
(426.5 mmol/l) was independently associated with mortality.
Similarly, Lassnigg et al.3 saw, in a cohort of patients who
underwent cardiac surgery, that either an increase of SCr
X0.5mg/dl (X44.2 mmol/l) or a decrease 40.3mg/dl
(426.5 mmol/l) was associated with worse survival. The
reasons why small alterations in SCr lead to increases in
hospital mortality are not entirely clear. Possible explanations
include the untoward effects of decreased kidney function
such as volume overload, retention of uremic compounds,
acidosis, electrolyte disorders, increased risk for infection,
and anemia.6 Although, these changes in SCr could simply be
colinear with unmeasured variables that lead to increased
mortality, multiple attempts to control for known clinical
variables has led to the consistent conclusion that decreased
kidney function is independently associated with outcome.
Furthermore, more severe reductions in kidney function tend
to be associated with even worse outcome as compared to
milder reductions.
Oliguria and anuria
Although urine output is both a reasonably sensitive
functional index for the kidney as well as a biomarker of
tubular injury, the relationship between urine output and
GFR, and tubular injury is complex. For example, oliguria
may be more profound when tubular function is intact.
Volume depletion and hypotension are profound stimuli for
vasopressin secretion. As a consequence the distal tubules and
collecting ducts become fully permeable to water. Concen-
trating mechanisms in the inner medulla are also aided
by low flow through the loops of Henle and thus, urine
volume is minimized and urine concentration maximized
(4500mOsmol/kg). Conversely, when the tubules are
injured, maximal concentrating ability is impaired and urine
volume may even be normal (i.e., nonoliguric renal failure).
Analysis of the urine to determine tubular function has a
long history in clinical medicine. Indeed, a high urine
osmolality coupled with a low urine sodium in the face of
oliguria and azotemia is strong evidence of intact tubular
function. However, this should not be interpreted as
‘‘benign’’ or even prerenal azotemia. Intact tubular function,
particularly early on, may be seen with various forms of renal
disease (e.g., glomerulonephritis). Sepsis, the most common
condition associated with ARF in the intensive-care unit
(ICU)7 may alter renal function without any characteristic
changes in urine indices.8,9 Automatically classifying these
abnormalities as ‘‘prerenal’’ will undoubtedly lead to
incorrect management decisions. Classification as ‘‘benign
azotemia’’ or ‘‘acute renal success’’ is not consistent with
available evidence. Finally, although severe oliguria and even
anuria may result from renal tubular damage, it can also be
caused by urinary tract obstruction and by total arterial or
venous occlusion. These conditions will result in rapid and
irreversible damage to the kidney and require prompt
recognition and management.
Acute tubular necrosis (ATN)
When mammalian kidneys are subjected to prolonged warm
ischemia followed by reperfusion, there is extensive necrosis
destroying the proximal tubules of the outer stripe of the
medulla, and the proximal convoluted tubules become
necrotic as well.10 Distal nephron involvement in these
animal experiments is minimal, unless medullary oxygena-
tion is specifically targeted.11 Although these animals develop
severe ARF, as noted by Rosen and Heyman, not much else
resembles the clinical syndrome in humans.12 Indeed these
authors correctly point out that the term ‘‘acute tubular
necrosis does not accurately reflect the morphological
changes in this condition’’.12 Instead, the term ATN is used
to describe a clinical situation in which there is adequate
renal perfusion to largely maintain tubular integrity, but not
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to sustain glomerular filtration. Data from renal biopsies in
patients with ATN dating back to the 1950s13 confirm the
limited parenchymal compromise in spite of severe organ
dysfunction.12 Thus, the syndrome of ATN has very little to
do with the animal models traditionally used to study it.
More recently, investigators have emphasized the role of
endothelial dysfunction, coagulation abnormalities, systemic
inflammation, endothelial dysfunction, and oxidative stress
in causing renal injury, particularly in the setting of
sepsis.14,15 True ATN does, in fact, occur. For example,
patients with arterial catastrophes (ruptured aneurysms,
acute dissection) can suffer prolonged periods of warm
ischemia just like animal models. However, these cases
comprise only a small fraction of patients with AKI, and
ironically, these patients are often excluded from studies
seeking to enroll patients with the more common clinical
syndrome known as ATN.
ARF
In a recent review, Eknoyan notes that the first description of
ARF, then termed ischuria renalis, was by William Heberden
in 1802.16 At the beginning of the twentieth century, ARF,
then named Acute Bright’s disease, was well described in
William Osler’s Textbook for Medicine (1909), as a consequence
of toxic agents, pregnancy, burns, trauma, or operations on the
kidneys. During the First World War the syndrome was named
‘‘war nephritis’’,17 and was reported in several publications.
The syndrome was forgotten until the Second World War,
when Bywaters and Beall published their classical paper on
crush syndrome.18 However, it is Homer W. Smith who is
credited for the introduction of the term ‘‘acute renal failure’’,
in a chapter on ‘‘Acute renal failure related to traumatic
injuries’’ in his textbook The kidney-structure and function in
health and disease (1951). Unfortunately, a precise biochemical
definition of ARF was never proposed and, until recently, there
was no consensus on the diagnostic criteria or clinical
definition of ARF, resulting in multiple different definitions.
A recent survey revealed the use of at least 35 definitions in the
literature.19 This state of confusion has given rise to wide
variation in reported incidence and clinical significance of
ARF. Depending on the definition used, ARF has been
reported to affect from 1% to 25% of ICU patients and has
lead to mortality rates from 15–60%.7,20,21
RIFLE criteria
The Acute Dialysis Quality Initiative (ADQI) group developed
a system for diagnosis and classification of a broad range of
acute impairment of kidney function through a broad
consensus of experts.22 The characteristics of this system are
summarized in Figure 1. The acronym RIFLE stands for the
increasing severity classes Risk, Injury, and Failure; and the two
outcome classes, Loss and End-Stage Renal Disease (ESRD).
The three severity grades are defined on the basis of the
changes in SCr or urine output where the worst of each
criterion is used. The two outcome criteria, Loss and ESRD,
are defined by the duration of loss of kidney function.
AKI: acute kidney injury/impairment
Importantly, by defining the syndrome of acute changes in
renal function more broadly, RIFLE criteria move beyond
ARF. The term ‘‘acute kidney injury/impairment’’ has been
proposed to encompass the entire spectrum of the syndrome
from minor changes in markers of renal function to
requirement for renal replacement therapy (RRT).23 Thus,
the concept of AKI, as defined by RIFLE creates a new
paradigm. AKI is not ATN, nor is it renal failure. Instead, it
encompasses both and also includes other, less severe
conditions. Indeed, as a syndrome, it includes patients
without actual damage to the kidney but with functional
impairment relative to physiologic demand. Including such
patients in the classification of AKI is conceptually attractive
because these are precisely the patients that may benefit from
early intervention. However, it means that AKI includes both
injury and/or impairment. Rather than focusing exclusively
on patients with renal failure or on those who receive dialysis
or on those that have a clinical syndrome defined by
pathology, which is usually absent (ATN), the strong
association of AKI with hospital mortality demands that we
change the way we think about this disorder. In a study by
Hoste et al.,2 only 14% of patients reaching RIFLE ‘‘F’’
received RRT, yet these patients experienced a hospital
mortality rate more than five times that of the same ICU
population without AKI. Is renal support underutilized or
delayed? Are there other supportive measures that should be
employed for these patients? Sustained AKI leads to profound
alterations in fluid, electrolyte, acid-base and hormonal
regulation. AKI results in abnormalities in the central
nervous, immune, and coagulation systems. Many patients
Figure 1 | The RIFLE criteria for AKI. ARF, acute renal failure; GFR,
glomerular filtration rate; Screat, serum creatinine concentration;
UO, urine output. Reprinted from Bellomo R, Ronco C, Kellum JA,
et al. Acute renal failure—definition, outcome measures, animal
models, fluid therapy and information technology needs: the
Second International Consensus Conference of the Acute Dialysis
Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-212 with
permission from Bellomo R et al.;22 accessed http://ccforum.com/
content/8/4/R204
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with AKI already have multisystem organ failure. What is the
incremental influence of AKI on remote organ function and
how does it affect outcome? A recent study by Levy et al.
examined outcomes for over 1000 patients enrolled in the
control arms of two large sepsis trials.24 Early improvement
(within 24 hours) in cardiovascular (P¼ 0.0010), renal
(Po0.0001), or respiratory (P¼ 0.0469) function was
significantly related to survival. This study suggests that
outcomes for patients with severe sepsis in the ICU are
closely related to early resolution of AKI. While rapid
resolution of AKI may simply be a marker of a good
prognosis, it may also indicate a window of therapeutic
opportunity to improve outcome in such patients.
Validation studies using RIFLE
As of early 2010, over half a million patients have been
studied to evaluate the RIFLE criteria as a means of
classifying patients with AKI.25–28 Large series from the
USA,28 Europe,29,30 and Australia,25 each including several
thousand patients, have provided a consistent picture. AKI
defined by RIFLE is associated with significantly decreased
survival and furthermore, increasing severity of AKI defined
by RIFLE stage leads to increased risk of death.
An early study from Uchino et al. focused on the
predictive ability of the RIFLE classification in a cohort
of 20 126 patients admitted to a teaching hospital for
424 hours over a 3-year period.5 The authors used an
electronic laboratory database to classify patients into
RIFLE-R, I, and F and followed them to hospital discharge
or death. Nearly 10% of patients achieved a maximum
RIFLE-R, 5% I, and 3.5% F. There was a nearly linear
increase in hospital mortality with increasing RIFLE class,
with patients at R having more than three times the mortality
rate of patients without AKI. Patients with I had close to
twice the mortality of R and patients with F had 10 times
the mortality rate of hospitalized patients without AKI.
The investigators performed multivariate logistic regression
analysis to test whether RIFLE classification was an
independent predictor of hospital mortality. They found
that class R carried an odds ratio of hospital mortality of 2.5,
I of 5.4, and F of 10.1.
Ali et al. studied the incidence of AKI in Northern
Scotland, a geographical population base of 523 390. The
incidence of AKI was 2147 per million population.31 Sepsis
was a precipitating factor in 47% of patients. RIFLE
classification was useful for predicting recovery of renal
function (Po0.001), requirement for RRT (Po0.001), length
of hospital stay for survivors (Po0.001), and in-hospital
mortality (P¼ 0.035). Although no longer statistically
significant, subjects with AKI had a high mortality at 3 and
6 months as well.
More recently, the Acute Kidney Injury Network (AKIN),
an international network of AKI researchers, organized a
summit of nephrology and critical care societies from around
the world. The group endorsed the RIFLE criteria with
a small modification to include small changes in SCr
(X0.3mg/dl or X26.5 mmol/l) when they occur within a
48-hour period.23 Two recent studies examining large
databases in the USA28 and Europe29 validated these
modified criteria. Thakar et al. found that increased severity
of AKI was associated with an increased risk of death
independent of comorbidity.28 Patients with Stage 1
(X0.3mg/dl or X26.5 mmol/l) increase in SCr but less than
a two-fold increase had an odds ratio of 2.2; with Stage 2
(corresponding to RIFLE-I), there was an odds ratio of 6.1;
and in Stage 3 (RIFLE-F), an odds ratio of 8.6 for hospital
mortality was calculated. An additional modification to the
RIFLE criteria has been proposed for pediatric patients in
order to better classify small children with acute-on-chronic
disease.32
Limitations to current definitions for AKI
Unfortunately, the existing criteria—while extremely useful
and widely validated—are still limited. First, despite efforts to
standardize the definition and classification of AKI, there is
still inconsistency in application.26,27 A minority of studies
have included urinary output criteria despite its apparent
ability to identify additional cases6,29 and many studies have
excluded patients whose initial SCr is already elevated.
Preliminary data from a 20 000-patient database from the
University of Pittsburgh suggests that roughly a third of AKI
cases are community-acquired33 and many cases may be
missed by limiting analysis to documented increases in SCr.
Indeed, the majority of cases of AKI in the developing world
are likely to be community-acquired. Thus, few studies can
provide accurate incidence data. An additional problem
relates to the limitations of SCr and urine output for
detecting AKI. In the future, biomarkers of renal cell injury
may identify additional patients with AKI and may identify
the majority of patients at an earlier stage.
Rationale for a guideline on AKI
AKI is a global problem and occurs in the community, in the
hospital where it is common on medical, surgical, pediatric,
and oncology wards, and in ICUs. Irrespective of its nature,
AKI is a predictor of immediate and long-term adverse
outcomes. AKI is more prevalent in (and a significant risk
factor for) patients with chronic kidney disease (CKD).
Individuals with CKD are especially susceptible to AKI
which, in turn, may act as a promoter of progression of the
underlying CKD. The burden of AKI may be most significant
in developing countries34,35 with limited resources for the
care of these patients once the disease progresses to kidney
failure necessitating RRT. Addressing the unique circum-
stances and needs of developing countries, especially in the
detection of AKI in its early and potentially reversible stages
to prevent its progression to kidney failure requiring dialysis,
is of paramount importance.
Research over the past decade has identified numerous
preventable risk factors for AKI and the potential of
improving their management and outcomes. Unfortunately,
these are not widely known and are variably practiced
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worldwide, resulting in lost opportunities to improve the care
and outcomes of patients with AKI. Importantly, there is no
unifying approach to the diagnosis and care of these patients.
There is a worldwide need to recognize, detect, and intervene
to circumvent the need for dialysis and to improve outcomes
of AKI. The difficulties and disadvantages associated with an
increasing variation in management and treatment of
diseases that were amplified in the years after the Second
World War, led in 1989 to the creation in the USA of the
Agency for Health Care Policy and Research (now the Agency
for Healthcare Research and Quality). This agency was
created to provide objective, science-based information to
improve decision making in health-care delivery. A major
contribution of this agency was the establishment of a
systematic process for developing evidence-based guidelines.
It is now well accepted that rigorously developed, evidence-
based guidelines, when implemented, have improved quality,
cost, variability, and outcomes.36,37
Realizing that there is an increasing prevalence of acute
(and chronic) kidney disease worldwide and that the
complications and problems of patients with kidney disease
are universal, Kidney Disease: Improving Global Outcomes
(KDIGO), a nonprofit foundation, was established in 2003
‘‘to improve the care and outcomes of kidney disease patients
worldwide through promoting coordination, collaboration,
and integration of initiatives to develop and implement
clinical practice guidelines’’.38
Besides developing guidelines on a number of other
important areas of nephrology, the Board of Directors
of KDIGO quickly realized that there is room for improving
international cooperation in the development, dissemi-
nation, and implementation of clinical practice guide-
lines in the field of AKI. At its meeting in December of
2006, the KDIGO Board of Directors determined that the
topic of AKI meets the criteria for developing clinical practice
guidelines.
These criteria were formulated as follows:
K AKI is common.
K AKI imposes a heavy burden of illness (morbidity and
mortality).
K The cost per person of managing AKI is high.
K AKI is amenable to early detection and potential prevention.
K There is considerable variability in practice to prevent,
diagnose, treat, and achieve outcomes of AKI.
K Clinical practice guidelines in the field have the potential
to reduce variations, improve outcomes, and reduce costs.
K Formal guidelines do not exist on this topic.
Summary
Small changes in kidney function in hospitalized patients are
important and associated with significant changes in short-
and long-term outcomes. The shift of terminology from ATN
and ARF to AKI has been well received by the research and
clinical communities. RIFLE/AKIN criteria provide a uni-
form definition of AKI, and have become the standard for
diagnostic criteria. AKI severity grades represent patient
groups with increasing severity of illness as illustrated by an
increasing proportion of patients treated with RRT, and
increasing mortality. Thus, AKI as defined by the RIFLE
criteria is now recognized as an important syndrome,
alongside other syndromes such as acute coronary syndrome,
acute lung injury, and severe sepsis and septic shock. The
RIFLE/AKIN classification for AKI is quite analogous to the
Kidney Disease Outcomes Quality Initiative (KDOQI) for
CKD staging, which is well known to correlate disease
severity with cardiovascular complications and other mor-
bidities.39 As CKD stages have been linked to specific
treatment recommendations, which have proved extremely
useful in managing this disease,39 we have developed
recommendations for evaluation and management of
patients with AKI using this stage-based approach.
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Chapter 1.2: Methodology
INTRODUCTION
This chapter provides a very brief summary of the methods
used to develop this guideline. Detailed methods are
provided in Appendix F. The overall aim of the project was
to create a clinical practice guideline with recommendations
for AKI using an evidence-based approach. After topics and
relevant clinical questions were identified, the pertinent
scientific literature on those topics was systematically
searched and summarized.
Group member selection and meeting process
The KDIGO Co-Chairs appointed the Co-Chairs of the Work
Group, who then assembled the Work Group to be responsible
for the development of the guideline. The Work Group consisted
of domain experts, including individuals with expertise in
nephrology, critical care medicine, internal medicine, pediatrics,
cardiology, radiology, infectious diseases and epidemiology. For
support in evidence review, expertise in methods, and guideline
development, the NKF contracted with the Evidence Review
Team (ERT) based primarily at the Tufts Center for Kidney
Disease Guideline Development and Implementation at Tufts
Medical Center in Boston, Massachusetts, USA. The ERT
consisted of physician-methodologists with expertise in nephrol-
ogy and internal medicine, and research associates and assistants.
The ERT instructed and advised Work Group members in all
steps of literature review, critical literature appraisal, and
guideline development. The Work Group and the ERT
collaborated closely throughout the project. The Work Group,
KDIGO Co-Chairs, ERT, liaisons, and NKF support staff met for
four 2-day meetings for training in the guideline development
process, topic discussion, and consensus development.
Evidence selection, appraisal, and presentation
We first defined the topics and goals for the guideline and
identified key clinical questions for review. The ERT
performed literature searches, organized abstract and article
screening, coordinated methodological and analytic processes
of the report, defined and standardized the search methodol-
ogy, performed data extraction, and summarized the
evidence. The Work Group members reviewed all included
articles, data extraction forms, summary tables, and evidence
profiles for accuracy and completeness. The four major topic
areas of interest for AKI included: i) definition and
classification; ii) prevention; iii) pharmacologic treatment;
and iv) RRT. Populations of interest were those at risk for
AKI (including those after intravascular contrast-media
exposure, aminoglycosides, and amphotericin) and those
with or at risk for AKI with a focus on patients with sepsis or
trauma, receiving critical care, or undergoing cardiothoracic
surgery. We excluded studies on AKI from rhabdomyolysis,
specific infections, and poisoning or drug overdose. Overall,
we screened 18 385 citations.
Outcome selection judgments, values, and preferences
We limited outcomes to those important for decision making,
including development of AKI, need for or dependence on
RRT, and all-cause mortality. When weighting the evidence
across different outcomes, we selected as the ‘‘crucial’’ outcome
that which weighed most heavily in the assessment of the
overall quality of evidence. Values and preferences articulated
by the Work Group included: i) a desire to be inclusive in
terms of meeting criteria for AKI; ii) a progressive approach to
risk and cost such that, as severity increased, the group put
greater value on possible effectiveness of strategies, but
maintained high value for avoidance of harm; iii) intent to
guide practice but not limit future research.
Grading the quality of evidence and the strength of
recommendations
The grading approach followed in this guideline is adopted
from the GRADE system.40,41 The strength of each recom-
mendation is rated as level 1 which means ‘‘strong’’ or level 2
which means ‘‘weak’’ or discretionary. The wording corres-
ponding to a level 1 recommendation is ‘‘We recommendy
should’’ and implies that most patients should receive the
course of action. The wording for a level 2 recommendation
is ‘‘We suggestymight’’ which implies that different choices
will be appropriate for different patients, with the suggested
course of action being a reasonable choice in many patients.
In addition, each statement is assigned a grade for the quality
of the supporting evidence, A (high), B (moderate), C (low),
or D (very low). Table 1 shows the implications of the
guideline grades and describes how the strength of the
recommendations should be interpreted by guideline users.
Furthermore, on topics that cannot be subjected to
systematic evidence review, the Work Group could issue
statements that are not graded. Typically, these provide
guidance that is based on common sense, e.g., reminders of
the obvious and/or recommendations that are not sufficiently
specific enough to allow the application of evidence. The
GRADE system is best suited to evaluate evidence on
comparative effectiveness. Some of our most important
guideline topics involve diagnosis and staging or AKI, and
here the Work Group chose to provide ungraded statements.
These statements are indirectly supported by evidence on risk
relationships and resulted from unanimous consensus of the
Work Group. Thus, the Work Group feels they should not be
viewed as weaker than graded recommendations.
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Table 1 | Implications of the strength of a recommendation
Implications
Grade* Patients Clinicians Policy
Level 1
‘‘We recommend’’
Most people in your situation
would want the recommended
course of action and only a
small proportion would not.
Most patients should receive the
recommended course of action.
The recommendation can be evaluated as
a candidate for developing a policy or a
performance measure.
Level 2
‘‘We suggest’’
The majority of people in your
situation would want the
recommended course of action,
but many would not.
Different choices will be appropriate for
different patients. Each patient needs help to
arrive at a management decision consistent
with her or his values and preferences.
The recommendation is likely to require
substantial debate and involvement of
stakeholders before policy can be
determined.
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